Atea Pharmaceuticals (AVIR) Accounts Payables (2019 - 2026)

Atea Pharmaceuticals' Accounts Payables history runs 8 years deep, the most recent figure standing at $9.4 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 27.87% year-over-year to $9.4 million in Q1 2026; TTM through Mar 2026 was $9.4 million, a 27.87% increase from a year earlier, with the FY2025 full-year figure at $12.9 million, up 190.38% from the prior year.
• Accounts Payables eased to $9.4 million in Q1 2026 per AVIR's latest filing, from $12.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $21.1 million in Q1 2024 and bottomed at $395000.0 in Q3 2023.
• The 5-year median for Accounts Payables is $4.5 million (2024), against an average of $6.4 million.
• Across the five-year window, Accounts Payables sank 94.96% in 2022 and jumped 2919.57% in 2024, its largest moves.
• Year by year, Accounts Payables stood at $2.6 million in 2022, then jumped by 66.68% to $4.3 million in 2023, then increased by 4.84% to $4.5 million in 2024, then jumped by 190.38% to $12.9 million in 2025, then fell by 27.03% to $9.4 million in 2026.
• Per Business Quant, the three latest AVIR Accounts Payables figures stand at $9.4 million (Q1 2026), $12.9 million (Q4 2025), and $3.5 million (Q3 2025).